Shares of molecular diagnostics firm Genetic Technologies Limited (GENE) are up $1.16, or 28%, at $5.38, in early trading, after the company this morning announced that a further two new breast health centers will begin to offer BREVAGenplus to their at-risk patients in a systematic fashion. Genetic Tech said that this is in addition to the six breast health centers that the company previously announced were set to adopt BREVAGenplus, of which all six have in fact provided samples during the March 2015 quarter.
More than 11 million GENE shares have exchanged hands as of 10:38 am EDT compared to its average daily volume of 2.79 million shares. The name has ranged in a price between $5.23-$6.00 after having opened the day at $5.43 as compared to the previous trading day’s close of $4.23.
Leave a Reply